Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NgG 12.5 µg investigational vaccine · 1 trial · 1 indication
Assessed solicited administration site events included injection site pain, erythema (redness), and swelling. Any = occurrence of the event regardless of intensity grade.
Assessed solicited systemic events included headache, fatigue (tiredness), myalgia (muscle pain), arthralgia (joint pain), and fever (pyrexia). Fever is defined as body temperature \>=38ºC; preferred location for measuring the temperature is oral cavity. Any = occurrence of the event regardless of intensity grade.
An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade.
An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade.
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact. Any = occurrence of the event regardless of intensity grade.
The safety laboratory data included haematological parameters \[hemoglobin, lymphocytes, platelets, neutrophils, and white blood cells (WBC)\] and biochemical parameters (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\], Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 1 (baseline) and Day 8 haematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Incidence of first confirmed gonorrhea cases by positive Nucleic Acid Amplification Test (NAAT) at the anorectal and/or urogenital location were evaluated. The incidence rate (y/PT) of confirmed gonorrhea cases, expressed in terms of 100 person-years, was calculated as the number of confirmed gonorrhea cases (y) in a group, over the sum of individual person-times at risk (PT) in the same group, and multiplied by 100.
Assessed solicited administration site events included injection site pain, erythema (redness), and swelling. Any = occurrence of the event regardless of intensity grade.
Assessed solicited systemic events included headache, fatigue (tiredness), myalgia (muscle pain), arthralgia (joint pain), and fever (pyrexia). Fever is defined as body temperature \>=38ºC; preferred location for measuring the temperature is oral cavity. Any = occurrence of the event regardless of intensity grade.
An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade.
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact. Any = occurrence of the event regardless of intensity grade.
The safety laboratory data included haematological parameters (hemoglobin, lymphocytes, platelets, neutrophils, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 1 (baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
The safety laboratory data included haematological parameters (hemoglobin, absolute lymphocyte count, platelets, absolute neutrophil count, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 1 (baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Unknown = No results are available for the corresponding laboratory parameter at the specific timepoint.
The safety laboratory data included haematological parameters (hemoglobin, lymphocytes, platelets, neutrophils, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 61 (baseline) and Day 68 haematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Unknown = No results are available for the corresponding laboratory parameter at the specific timepoint.
The safety laboratory data included haematological parameters (hemoglobin, absolute lymphocyte count, platelets, absolute neutrophil count, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 61 (baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Unknown = No results are available for the corresponding laboratory parameter at the specific timepoint.
| Arm | Type | Description |
|---|---|---|
| Phase 1: Neisseria gonorrhoeae GMMA (NgG) 12.5 micrograms (µg) Group | EXPERIMENTAL | Participants received 2 doses of NgG 12.5 µg investigational vaccine on Day 1 and Day 61. |
| Phase 1: NgG 25 µg Group | EXPERIMENTAL | Participants received 2 doses of NgG 25 µg investigational vaccine on Day 1 and Day 61. |
| Phase 1: NgG 50 µg Group | EXPERIMENTAL | Participants received 2 doses of NgG 50 µg investigational vaccine on Day 1 and Day 61. |
| Phase 1: Placebo Group | PLACEBO_COMPARATOR | Participants received 2 doses of placebo on Day 1 and Day 61. |
| Phase 2: NgG Highest tolerated dose (HTD; 50 µg) Group | EXPERIMENTAL | Participants received 2 doses of NgG HTD (50 µg) investigational vaccine on Day 1 and Day 61. The HTD was selected based on the safety evaluation performed in Phase 1. |
| Phase 2: NgG dose below HTD (bHTD; 25 µg) Group | EXPERIMENTAL | Participants received 2 doses of NgG bHTD (25 µg) investigational vaccine on Day 1 and Day 61. The bHTD is selected based on the safety evaluation performed in Phase 1. |
| Phase 2: Placebo Group | PLACEBO_COMPARATOR | Participants received 2 doses of placebo on Day 1 and Day 61. |
| Name | Type | Description |
|---|---|---|
| NgG 12.5 µg investigational vaccine | BIOLOGICAL | 2 doses of NgG 12.5 µg investigational vaccine administered intramuscularly. |
| NgG 25 µg investigational vaccine | BIOLOGICAL | 2 doses of NgG 25 µg investigational vaccine administered intramuscularly. |
| NgG 50 µg investigational vaccine | BIOLOGICAL | 2 doses of NgG 50 µg investigational vaccine administered intramuscularly. |
| Placebo | COMBINATION_PRODUCT | 2 doses of placebo administered intramuscularly. |
Inclusion Criteria: Inclusion criteria for the dose-escalation safety lead-in part * Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written or witnessed/thumb printed informed consent obtained from the participant prior to perfor...
NgG 12.5 µg investigational vaccine is being developed for the prevention of sexually transmitted diseases, specifically infections caused by Neisseria gonorrhoeae. It is an investigational vaccine intended for healthy adults aged 18 to 50 years. The vaccine is currently in clinical development and has not been approved for use.
NgG 12.5 µg investigational vaccine is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the safety and efficacy of this investigational vaccine for sexually transmitted diseases.
NgG 12.5 µg investigational vaccine is in Phase 1 clinical development. It is an investigational product, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains under investigation for its safety and efficacy in preventing sexually transmitted diseases.
NgG 12.5 µg investigational vaccine has one completed clinical trial registered as NCT05630859. This Phase 1 study, titled 'Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age,' enrolled 1009 participants across multiple countries including the United States, Brazil, France, Germany, Philippines, South Africa, Spain, and the United Kingdom.
Yes, NgG 12.5 µg investigational vaccine is the same as the GSK Neisseria Gonorrhoeae GMMA (NgG) investigational vaccine. The clinical trial NCT05630859 refers to the vaccine as 'GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine,' and NgG 12.5 µg is the dose formulation being studied.